-
Article
Erratum: A gene expression signature for high-risk multiple myeloma
Correction to: Leukemia (2012) 26, 2406–2413; doi:10.1038/leu.2012.127 Since the publication of this article, the authors have discovered an error in the script for calculating the IFM-15 risk scores. In their...
-
Article
A gene expression signature for high-risk multiple myeloma
There is a strong need to better predict the survival of patients with newly diagnosed multiple myeloma (MM). As gene expression profiles (GEPs) reflect the biology of MM in individual patients, we built a pro...
-
Article
Open AccessImproving the accuracy of pre-operative survival prediction in renal cell carcinoma with C-reactive protein
Validated objective biomarkers are needed for patients with renal cell carcinoma (RCC) to guide patient management and define high-risk populations for follow-up or for therapeutic purposes.
-
Article
Open AccessHigh-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin’s disease is unlikely to be associated with a major increased risk of secondary MDS/AML
Hodgkin’s disease is curable in the majority of patients, although a proportion of patients are resistant to or relapse after initial therapy. High-dose therapy with autologous stem cell support has become the...
-
Article
Combination chemotherapy for intermediate and high grade non-Hodgkin's lymphoma
One hundred and eighteen consecutive adults with newly diagnosed intermediate and high-grade non-Hodgkin's lymphoma were treated with chemotherapy comprising Doxorubicin, Cyclophosphamide, Vincristine and Pred...
-
Article
Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests
The influence of liver biochemistry tests on epirubicin pharmacokinetics has been investigated in 52 women with advanced breast cancer, 27 of whom had radiologically proven liver metastases. Patients received ...
-
Article
Patterns of survival in patients with advanced Hodgkin's disease (HD) treated in a single centre over 20 years
A total of 164 consecutive adults with newly confirmed stage IIIB, IVA or IVB Hodgkin's disease (HD) commenced cyclical combination chemotherapy comprising mustine, vinblastine, prednisolone and procarbazine (...
-
Article
High dose cytosine arabinoside in the initial treatment of adults with acute lymphoblastic leukaemia
In a study conducted at St Bartholomew's Hospital between 1972 and 1982, using moderately intensive therapy (OPAL/HEAV'D), a low blast count at presentation (less than 10 x 10(9) 1(-1)) and common ALL (C-ALL) ...
-
Chapter and Conference Paper
Intensive Chemotherapy for Acute Lymphoblastic Leukaemia in Adults
High-dose cytosine arabinoside (HD Ara-C) has been shown to induce complete remission in acute lymphoblastic leukaemia (ALL) which is refractory to, or which has recurred following conventional therapy [1–5]. ...
-
Chapter
Systems: Past, Present, and Future
The question concerning the necessity of this paper must arise since, we frequently read, systems science is recognised as “coming together” merely 40 to 50 years ago. We contend that (a) this view can be fund...
-
Article
Failure to preserve fertility in patients with Hodgkin's disease
The hypothesis that the “down-regulated” gonad is less vulnerable to the effects of cytotoxic chemotherapy for advanced Hodgkin's disease has been investigated. Thirty men and eighteen women were randomly allo...
-
Chapter and Conference Paper
The Treatment of Acute Myelogenous Leukemia
It has recently been suggested that it is possible to cure at least 25% of younger adults who have acute myelogenous leukaemia [1], The results achieved at St. Bartholomew’s Hospital, London, demonstrate this ...
-
Article
Monoclonal antibody assay of serum placental alkaline phosphatase in the monitoring of testicular tumours
A monoclonal antibody (H17E2) recognising both placental alkaline phosphatase (PLAP) and testicular PLAP-like alkaline phosphatase was incorporated in a solid phase immunoassay. This was used to measure levels...
-
Chapter
Short Term Chemotherapy for Acute Myelogenous Leukaemia
The use of increasingly intensive chemotherapy for the treatment of acute nyelogenous leukaemia has led to an apparent improvement in the prognosis of younger patients. It has become possible to support them e...
-
Chapter and Conference Paper
Comparison of Clinical Trials in Acute Myelogenous Leukaemia by use of a Mathematical Model
We describe the development and application to clinical trials of a mathematical model of patient behaviour in acute myelogenous leukamia (AML). Observed patient behaviour in a trial can be compared with predi...
